Bitcoin pioneer Charlie Shrem peels back the layers on the lives and backgrounds of the world's most impactful innovators. Centering around intimate narratives, Shrem uncovers a detailed, previously unspoken story of the genesis and evolution of bitcoin, cryptocurrency, artificial intelligence, and the web3 movements. Join Shrem as he journeys through the uncharted territories of tech revolutions, revealing the human side of the stories that shaped the digital world we live in today.
…
continue reading
المحتوى المقدم من Proactive Investors. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Proactive Investors أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
Player FM - تطبيق بودكاست
انتقل إلى وضع عدم الاتصال باستخدام تطبيق Player FM !
انتقل إلى وضع عدم الاتصال باستخدام تطبيق Player FM !
Amplia Therapeutics: Advancing Pancreatic Cancer Treatment
MP3•منزل الحلقة
Manage episode 435437094 series 2891889
المحتوى المقدم من Proactive Investors. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Proactive Investors أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
Chris Burns, CEO of Amplia Therapeutics, shared promising updates with Steve Darling from Proactive regarding the company’s ongoing Phase 2a clinical trial focused on treating advanced pancreatic cancer. Burns announced that a fifth patient enrolled in the trial has achieved a confirmed partial response, indicating a 30% or greater reduction in the overall size of tumor lesions, which has been maintained over a two-month period with no new tumor lesions appearing. Additionally, Burns reported that six other patients in the trial have shown stable disease at both their two-month and four-month assessment time points. According to RECIST 1.1 criteria, stable disease (SD) is noted when tumor lesions have either reduced in size by less than 30% or have shown minimal to no growth. The Phase 2a ACCENT trial is exploring the efficacy of Amplia Therapeutics’ lead asset, narmafotinib, in treating advanced pancreatic cancer. The trial plans to enroll a total of 50 patients, with the first cohort consisting of 26 patients. Responses to the therapy are monitored every two months, and the recruitment of the second cohort of 24 patients will commence once a minimum of six patients have recorded a confirmed partial or complete response. #proactiveinvestors #ampliatherapeuticslimited #asx #atx #PancreaticCancer #CancerTreatment #ClinicalTrial #Biotech #HealthcareInnovation #Pharmaceuticals #Oncology #CancerResearch #MedicalBreakthrough#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
624 حلقات
MP3•منزل الحلقة
Manage episode 435437094 series 2891889
المحتوى المقدم من Proactive Investors. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Proactive Investors أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
Chris Burns, CEO of Amplia Therapeutics, shared promising updates with Steve Darling from Proactive regarding the company’s ongoing Phase 2a clinical trial focused on treating advanced pancreatic cancer. Burns announced that a fifth patient enrolled in the trial has achieved a confirmed partial response, indicating a 30% or greater reduction in the overall size of tumor lesions, which has been maintained over a two-month period with no new tumor lesions appearing. Additionally, Burns reported that six other patients in the trial have shown stable disease at both their two-month and four-month assessment time points. According to RECIST 1.1 criteria, stable disease (SD) is noted when tumor lesions have either reduced in size by less than 30% or have shown minimal to no growth. The Phase 2a ACCENT trial is exploring the efficacy of Amplia Therapeutics’ lead asset, narmafotinib, in treating advanced pancreatic cancer. The trial plans to enroll a total of 50 patients, with the first cohort consisting of 26 patients. Responses to the therapy are monitored every two months, and the recruitment of the second cohort of 24 patients will commence once a minimum of six patients have recorded a confirmed partial or complete response. #proactiveinvestors #ampliatherapeuticslimited #asx #atx #PancreaticCancer #CancerTreatment #ClinicalTrial #Biotech #HealthcareInnovation #Pharmaceuticals #Oncology #CancerResearch #MedicalBreakthrough#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
624 حلقات
Minden epizód
×مرحبًا بك في مشغل أف ام!
يقوم برنامج مشغل أف أم بمسح الويب للحصول على بودكاست عالية الجودة لتستمتع بها الآن. إنه أفضل تطبيق بودكاست ويعمل على أجهزة اندرويد والأيفون والويب. قم بالتسجيل لمزامنة الاشتراكات عبر الأجهزة.